BSH/UKMS Guidelines

Please find the link below to the most recent publication from NICE outlining Interim treatment change options during the COVID-19 pandemic issued on.  It is endorsed by NHS England. Some of options proposed for multiple myeloma are:

  • Allow oral pomalidomide with dexamethasone as second- or third-line therapy instead of intravenous treatments in patients previously treated with lenalidomide to reduce the need for chemotherapy and reduce admissions and risk of neutropenia.
  • Allow first-line lenalidomide and dexamethasone for transplant eligible myeloma patients in preference to regimens that require more hospital attendances and parenteral administrations to reduce toxicity of treatment and number of admissions required for treatment.
  • Allow second-line lenalidomide and dexamethasone for patients who have not been previously treated with bortezomib.

Please see link below to access the full document.

https://www.nice.org.uk/guidance/ng161

Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England — Chemotherapy Clinical Reference Group and and Cancer pharmacist

UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak

It is clear that the current outbreak is going to impact the ability to deliver healthcare for some months to come. This is especially the case for systemic anti-cancer therapy.

To try and mitigate the impact of changing capacity, and to minimise the risk that the immunosppressive effects of myeloma therapy has, the guidance in the below document has been compiled on 25th March 2020 to help support myeloma doctors in their decision-making and treatment planning.

COVID-19 Guidance — UKMF Executive Committee

Update Covid-19 Guidance May 2020 — UKMF Executive Committee

Please find the link below to the most recent publication from NICE outlining Interim treatment change options during the COVID-19 pandemic issued on.  It is endorsed by NHS England. Some of options proposed for multiple myeloma are:

  • Allow oral pomalidomide with dexamethasone as second- or third-line therapy instead of intravenous treatments in patients previously treated with lenalidomide to reduce the need for chemotherapy and reduce admissions and risk of neutropenia.
  • Allow first-line lenalidomide and dexamethasone for transplant eligible myeloma patients in preference to regimens that require more hospital attendances and parenteral administrations to reduce toxicity of treatment and number of admissions required for treatment.
  • Allow second-line lenalidomide and dexamethasone for patients who have not been previously treated with bortezomib.

Please see link below to access the full document.

https://www.nice.org.uk/guidance/ng161/resources/interim-treatment-change-options-during-the-covid19-pandemic-endorsed-by-nhs-england-pdf-8715724381

Interim treatment change options during the COVID-19 pandemic, endorsed by NHS England — Chemotherapy Clinical Reference Group and and Cancer pharmacist

UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak

It is clear that the current outbreak is going to impact the ability to deliver healthcare for some months to come. This is especially the case for systemic anti-cancer therapy.

To try and mitigate the impact of changing capacity, and to minimise the risk that the immunosppressive effects of myeloma therapy has, the guidance in the below document has been compiled on 25th March 2020 to help support myeloma doctors in their decision-making and treatment planning.

COVID-19 Guidance — UKMF Executive Committee

Update Covid-19 Guidance May 2020 — UKMF Executive Committee

Annual Report

Click here to visit our Annual Report page.

About Us

Find out more about the UK Myeloma Society.

Find out more

Annual Report

Click here to visit our Annual Report page.

Position Statement

Find out more about our Position Statements by clicking here.